-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 3, 2024

Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

Author(s)Stephanie L. Graff, MD

An expert on breast cancer reviews currently available tests for ESR1 mutations and provides clinical insights on best practices for testing.

Episodes in this series

EP. 1 Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP. 1 Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP. 2 Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP. 2 Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP. 3 Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP. 3 Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP. 4 ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP. 4 ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP. 5 Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP. 5 Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP. 6 Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP. 6 Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP. 7 Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP. 7 Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP. 8 Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

EP. 8 Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 9 Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 10 Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"

EP. 11 The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"

EP. 12 Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 13 Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Multidisciplinary Geriatric Oncology Improves Breast Cancer Care: Enrique Soto Perez de Celis, MD

BySabrina McCrear,Enrique Soto Perez de Celis, MD, PhD

July 29th 2026

Enrique Soto Perez de Celis

Older Adult Priorities Should Shape Breast Cancer Trial Design: Enrique Soto Perez de Celis, MD, PhD

BySabrina McCrear,Enrique Soto Perez de Celis, MD, PhD

July 28th 2026

Denise Yardley, MD | Image Credit: Sarah Cannon Research Institute

Breast Cancer De-Escalation Now Rests on Molecular Profiling: Denise Yardley, MD

ByElla Hohmann, MS,Denise Yardley, MD

July 28th 2026

Denver Skyline | Image Credit: © f11photo-stock.adobe.com

Precision Therapies Are Advancing Fast, and Care Delivery Has to Catch Up

BySabrina McCrear

July 28th 2026

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

5 FDA Firsts From June

ByBrooke McCormick

July 24th 2026

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps

Boston Panel Confronts Access and Coordination Gaps in Obesity Care